Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anmai Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead asset EMB-01 is the world's first EGFR/c-MET bispecific antibody in Phase II trials for colorectal cancer, showing potential to overcome resistance seen in single-target therapies and undergoing both monotherapy and combination chemo research; additional T-cell engager assets (EMB-06, EMB-07) advancing for BCMA/CD3 and ROR1/CD3 targets in cancer and immune indications
- Therapeutic areas
- OncologyImmunology
- Modalities
- Bispecific monoclonal antibodyT cell engagerMonoclonal antibody
- Industry
- Biotech
Beyond the preview
Go deeper on Anmai Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anmai Biotechnology.